Forgot Password?
Return to Course Listing

CME: Cold agglutinin disease (CAD): Updates from the American Society of Hematology (ASH) 2019 annual meeting

Activity Description / Statement of Need:

In this online, self-learning activity:

Cold agglutinin disease (CAD) is a subtype of autoimmune hemolytic anemia (AIHA) and characterized by cold agglutinin (CA) autoantibodies that cause the erythrocytic hemolysis. Also known as primary or idiopathic CAD, it is distinguished further from cold agglutinin syndrome (CAS), which is a complication of known conditions such as malignancy, infection, or autoimmune disease. Little is known about the epidemiology of CAD; one small study estimated incidence of 1 per 1 million people and prevalence of 1 per 16 million people with females twice as likely males to develop the disease and a median age of onset of 67 years.

This learning activity has been designed to educate and update HCPs’ knowledge of CAD management as well as improve related competence and performance.

Target Audience:

The following healthcare professionals (HCPs): hematologists, oncologists, immunologists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CAD.


Commercial Support Disclosure: This activity is supported by educational grants from Sanofi / Genzyme.

Learners may participate in this activity free of charge.


Release Date: February 21, 2020 -- Expiration Date: February 21, 2022

Faculty: Adrienne Phillips, MD

Agenda

Faculty introduction and disclosures

Introductory content: overview of CAD

  • Epidemiology
  • Pathogenesis
  • Symptoms, clinical presentation

Diagnostic tools and criteria

  • Diagnosis and differential diagnoses
  • Differences in diagnosing different subtypes of AIHA

CAD treatment

  • Non-pharmacologic strategies: cold-avoidance, plasmapheresis, surgical considerations
  • Pharmacologic therapy
    • Goals of therapy
    • Current treatment
    • Emerging therapies
    • Clinical trial evidence
    • Supportive care
    • Patient case(s)

Summary, conclusions, best practice recap


Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathogenesis and symptomology of AIHA generally and CAD specifically
  • Describe how diagnosis of CAD is distinguished from other subtypes of AIHA and challenges to successful identification of patients
  • Describe present and emerging treatment options for CAD and monitoring parameters for effectiveness of treatment
  • Develop a safe and clinically effective treatment plan including non-pharmacologic and pharmacologic therapy for patients with CAD

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of  1.00 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PhysiciansFor maintenance of certification (MOC) credit, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC credit for this activity. Please note: not all activities on this site provide MOC credit. If this activity does not specify that it provides MOC credit in this section, then it does NOT provide MOC credit.

Pharmacists 

ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This activity is approved for 1.00 hours (0.10 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-20-006-H01-P.  CPE credit effective 3/4/20 and expires 3/4/22. This is a Knowledge (K)-type activity.

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.  ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Adrianne Phillips, M.D. has no relevent financial disclosures. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevent financial disclosures.

Commercial Support Disclosure: This activity is supported by educational grants from Sanofi / Genzyme.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Atypical hemolytic uremic syndrome (aHUS): therapeutic updates and optimizing treatment

Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018)

Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies

Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices